Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis

2021 ◽  
Author(s):  
Emmanuel Bensignor ◽  
Emilie Videmont
Keyword(s):  
Atopic Dermatitis ◽  
Plant Extracts ◽  
Topical Therapy ◽  
Canine Atopic Dermatitis

Supplementary therapy in canine atopic dermatitis

2019 ◽  
Vol 24 (8) ◽  
pp. 400-407
Author(s):  
Sue Paterson
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Specific Immunotherapy ◽  
Essential Fatty Acids ◽  
Topical Therapy ◽  
Allergen Specific Immunotherapy ◽  
Canine Atopic Dermatitis ◽  
Adequate Control ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Therapy for canine atopic dermatitis can be described as foundation or supplementary. Foundation therapy, which refers to allergen-specific immunotherapy, ciclosporin, glucocorticoids, lokivetmab and oclacitinib, is needed in all but the mildest of cases of canine atopic dermatitis. Supplementary therapies include drugs such as antihistamines, essential fatty acids, topical therapy and other systemic anti-inflammatory drugs. While it is uncommon for any of these supplementary drugs to provide adequate control of many cases of canine atopic dermatitis, they can reduce the frequency of relapse and reduce the amount of foundation therapy that is required when used in combination with them.

scholarly journals Topical therapy in canine atopic dermatitis: new products

2020 ◽  
Vol 25 (2) ◽  
pp. 76-82
Author(s):  
Tim Nuttall
Keyword(s):  
Atopic Dermatitis ◽  
Biofilm Formation ◽  
Topical Therapy ◽  
Residual Activity ◽  
Canine Atopic Dermatitis ◽  
Topical Product ◽  
Ophiopogon Japonicus ◽  
Improve Compliance ◽  
Epidermal Morphology ◽  
The Ideal

Topical therapy in canine atopic dermatitis (CAD) can moisturise and soothe the skin; treat and prevent secondary bacterial and yeast infections; and remove debris, grease and allergens. Shampoos are commonly used but can be time-consuming. Non-rinsing wipes, foams and spot-on preparations facilitate topical application and improve compliance. The ideal topical product for CAD should be emollient, lipid-barrier sparing, microbiome balancing, easy to apply and well-tolerated, have some residual activity, and be safe for the dog and owner. Ophytrium is a novel Ophiopogon japonicus (Japanese mondo grass) derived product. It blocks inflammatory pathways, maintains epidermal morphology and barrier function, and reduces staphylococcal adherence and biofilm formation in human and canine epidermis models. It has been incorporated in shampoos and foams for dogs (Douxo S3®; Ceva Sante Animale, Libourne, France). Use of 3-week treatment cycles with one shampoo followed by a foam application every 2–3 days helps to ameliorate CAD (Douxo S3 Calm®) and superficial staphylococcal pyoderma (ophytrium/3% chlorhexidine; Douxo S3 Pyo®). Effective topical therapy used alone or alongside other modalities can improve the effectiveness and safety of treatment for CAD. Reducing the need for systemic antimicrobials is a vital part of antimicrobial stewardship.

scholarly journals IgE reactivity to Pacific cod (Gadus macrocephalus) fish allergens in dogs with canine atopic dermatitis

2019 ◽  
Vol 143 (2) ◽  
pp. AB67
Author(s):  
Ichiro Imanishi ◽  
Jumpei Uchiyama ◽  
Takako Matsuda ◽  
Keijiro Mizukami ◽  
Hidekatsu Shimakura ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pacific Cod ◽  
Canine Atopic Dermatitis ◽  
Ige Reactivity ◽  
Pacific Cod Gadus Macrocephalus ◽  
Gadus Macrocephalus

Evaluation of the cutaneous expression of IL-17, IL-22, IL-31, and their receptors in canine atopic dermatitis

2021 ◽  
Vol 136 ◽  
pp. 74-80
Author(s):  
Sayaka Shiomitsu ◽  
James Gillen ◽  
Salvatore Frasca ◽  
Domenico Santoro
Keyword(s):  
Atopic Dermatitis ◽  
Canine Atopic Dermatitis

Expression of thymic stromal lymphopoietin in canine atopic dermatitis

2013 ◽  
Vol 24 (1) ◽  
pp. 54-e14 ◽  
Author(s):  
Jolanta Klukowska-Rötzler ◽  
Ludovic Chervet ◽  
Eliane J. Müller ◽  
Petra Roosje ◽  
Eliane Marti ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Thymic Stromal Lymphopoietin ◽  
Canine Atopic Dermatitis

Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

2017 ◽  
Vol 181 (5) ◽  
pp. 118-118 ◽  
Author(s):  
I. Wagner ◽  
K. J. Geh ◽  
M. Hubert ◽  
G. Winter ◽  
K. Weber ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Mrna Expression ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Interferon Γ ◽  
Preliminary Evaluation ◽  
Cpg Odn ◽  
Canine Atopic Dermatitis ◽  
Group 2 ◽  
Group 1

Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are a promising new immunotherapeutic treatment option for canine atopic dermatitis (AD). The aim of this uncontrolled pilot study was to evaluate clinical and immunological effects of gelatine nanoparticle (GNP)-bound CpG ODN (CpG GNP) on atopic dogs. Eighteen dogs with AD were treated for 8 weeks (group 1, n=8) or 18 weeks (group 2, n=10). Before inclusion and after 2 weeks, 4 weeks, 6 weeks (group 1+2), 8 weeks, 12 weeks and 16 weeks (group 2) 75 µg CpG ODN/dog (bound to 1.5 mg GNP) were injected subcutaneously. Pruritus was evaluated daily by the owner. Lesions were evaluated and serum concentrations and mRNA expressions of interferon-γ, tumour necrosis factor-α, transforming growth factor-β, interleukin (IL) 10 and IL-4 (only mRNA expression) were determined at inclusion and after 8 weeks (group 1+2) and 18 weeks (group 2). Lesions and pruritus improved significantly from baseline to week 8. Mean improvements from baseline to week 18 were 23 per cent and 44 per cent for lesions and pruritus, respectively, an improvement of ≥50 per cent was seen in six out of nine and three out of six dogs, respectively. IL-4 mRNA expression decreased significantly. The results of this study show a clinical improvement of canine AD with CpG GNP comparable to allergen immunotherapy. Controlled studies are needed to confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document